Recruiting

NICardipine for Fast Achievement of Systolic BP Targets in ICH

Quality improvement study with a quasi-randomized design. The study monitors the effect of a gradually implemented treatment algorithm prioritizing intravenous antihypertensives (e.g., nicardipine) over long-acting nitrate patches. It aims to increase the proportion of patients reaching target systolic BP \<140 mmHg within 1 hour of hospital admission while monitoring safety, clinical outcomes, and healthcare resource utilization.

ClinicalTrials.gov IDNCT07044232

PhasePHASE4

Enrollment88

SponsorAarhus University Hospital

Age18 Years

SexALL

I'm interested View official listing

Conditions studied

Intracerebral Haemorrhage

About this study

Interventions

Combination Product: Nicardipine — Nicardipine infusion based acute blood pressure lowering treatment
Combination Product: Glyceryl trinitrate — Glyceryltrinitrate based acute blood pressure lowering treatment

Primary outcomes

Target blood pressure < 140 mmHg 1 hour after admission. (1 hour after stroke center admission)

Eligibility information

Inclusion Criteria: * Age ≥18 years * Acute spontaneous Intracerberal Hemorrhage confirmed by imaging * Symptom onset to stroke center admission \<6 hours * Elevated systolic blood pressure (\>140 mmHg) at admission Exclusion Criteria: * Secondary causes of ICH (e.g., trauma, vascular malformation) * Presumed fatal bleeding at admission * Short remaining life expectancy (\<12 month)

Study locations

Aarhus University Hospital, Aarhus, 8200 Denmark

Before you participate: Varda Clinical is an independent discovery tool, not the study sponsor or a medical provider. Eligibility can only be determined by the official study team. Discuss potential risks and benefits with a qualified healthcare professional.

Source: ClinicalTrials.gov. Record last refreshed by Varda Clinical: 2026-09-27.